Print
Email
Print Edition StoriesFriday, October 23, 2009
Nuclea wraps up $3.4 million funding
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
Following the Clean Energy Council Fellows
MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds
Nuclea Bioechnologies, based in Pittsfield and Worcester, closed out a $3.4 million equity deal originally announced in June with an investment by New York-based Private Equity Investors Inc., according to a filing with the U.S. Securities and Exchange Commission.
Founded in Pittsfield and with operations on the Clark University campus in Worcester, Nuclea is involved in biomarker research focused on cancer. The university is one of the company’s collaborators. Nuclea CEO Patrick J. Muraca is an alumnus of the school, according to the company. The company changed its name from Nuclea Biomarkers LLC a year ago when it announced that it was moving operations to Worcester.
In June , the company filed an SEC notice saying that it had raised $1 million of a planned $3 million round without identifying the eight investors. In the latest amendment, dated Wednesday, the company listed Private Equity Investors venture partner Richard Vietor as a director. Vietor also serves on the boards of biopharmaceutical company QLT Inc. of Vancouver, B.C., and pediatric drugs company InfaCare Pharmaceutical Corp. of Pennsylvania.
Muraca couldn’t be reached for comment.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.